Paliperidone
SGA • Brands: Invega
Last reviewed: 2025-09-23
General information
Indicated for: Paliperidone extended-release tablets are an atypical antipsychotic agent indicated for Treatment of schizophrenia (1.1) Adults: Efficacy was established in three 6-week trials and one maintenance trial. (14.1) Adolescents (ages 12 to 17): Efficacy was established in one 6-week trial. (14.1) Treatment of schizoaffective disorder as monotherapy and as an adjunct to mood stabilizers and/or antidepressants. (1.2) Efficacy was established in two 6-week trials in adult patients. (14.2)
Dosing & forms
- Forms/strengths: —
- Frequency: —
- Food: —
- Typical range: 3–12 mg/day (ER)
Mechanism (brief)
D2 and 5-HT2A antagonism; active metabolite of risperidone.
Metabolism & Half‑life
- Metabolism: Minimally hepatic, largely renal excretion unchanged.
- Half‑life: ~23 h (ER).
Therapeutic Drug Monitoring (TDM)
Recommended: No
View labelExact
Long‑acting injectable (LAI)
Monitoring highlights
- Prolactin if symptomatic — PRN
In‑depth reading
- Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview. — CNS Drugs (2021)
- 6‑month paliperidone palmitate (PP6M): review — Review (2021)
- Paliperidone palmitate long‑acting injection: efficacy and safety (review) — Review (2018)
- Paliperidone palmitate vs oral antipsychotics: comparative effectiveness — Observational (2017)
Sources
- Paliperidone label — DailyMed (2025)